Breast cancer patients with FGFR1 amplification had a poorer DMFS than patients without amplification (P = 0.04, unadjusted analysis); however, this difference in DMFS outcome did not achieve significance in the adjusted analysis (P = 0.05). The gene discussed is FGFR1; the disease is breast carcinoma.